A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02809781|
Recruitment Status : Recruiting
First Posted : June 22, 2016
Last Update Posted : June 24, 2016
|Condition or disease||Intervention/treatment||Phase|
|Spondylitis Spondylitis, Ankylosing Ankylosis Arthritis Spondylarthritis Spondylarthropathies Spinal Diseases Musculoskeletal Diseases Bone Diseases||Biological: Intravenous infusion of MSCs Drug: Etanercept||Phase 2 Phase 3|
Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease involving primarily the sacroiliac joints and the axial skeleton. The main clinical features are back pain and progressive stiffness of the spine. Oligoarthritis of the hips and shoulders, enthesopathy, and anterior uveitis are common, and involvement of the heart and lungs is rare. The current understanding of the pathogenesis of this disorder is limited.It mainly about to hereditary susceptibility (eg HLA-B27),infection and autoimmunity.
Although traditional drugs, such as Nonsteroidal antiinflammatory drugs (NSAIDs) disease-modifying antirheumatic drugs (DMARDs such as methotrexate, salicylazosulfapyridine OR thalidomide) and steroids have been used in the treatment of AS, however, many studies have indicated that the overall response to these drugs is not satisfied. Addition, the severe side effects of these drugs have also been observed. The management of AS patients therefore remains unsatisfactory and targeted therapies are needed. Although the application of TNF alpha receptor inhibitor (such as Etanercept) has got the success in the early treatment of ankylosing spondylitis, the tolerance to this biological agent make the therapy to this disease rather difficult. Recently, owning to its immunoregulatory, immunosuppressive, stimulating hematopoiesis and tissue repairing properties, the infusion of human MSCs isolated from human bone marrow have been a promising and effective treatment to AS patients. This study will evaluate the safety and effectiveness of MSC transplantation in the AS patients and compare the efficiency with the Etanercept to treat AS patients.
This study will last 2 to 3 years. Participants will be randomly assigned to receive either MSC transplant therapy (experimental group) or Etanercept therapy (control group). Patients will undergo MSC transplant at the start of the study on Day 0. The experimental group will receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks, totally for 12 weeks. After 3 months, patients will receive the second MSC transplantation. After 12 weeks (Phase I) and 48 weeks (Phase II) from the first transplantation, patients will be evaluated.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||250 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS|
|Study Start Date :||June 2016|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: Intravenous infusion of MSCs
Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
Biological: Intravenous infusion of MSCs
Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
Active Comparator: Etanercept
50mg,hypodermic injection,once per week, for 12 weeks
50mg,hypodermic injection,once per week, for 12 weeks
Other Name: TNF alpha receptor inhibitor
- The Assessment of Spondyloarthritis International Society (ASAS)20 response [ Time Frame: 48 weeks ]ASAS measures symptomatic improvement in AS patients.ASAS=4 domains:patient global assessment of disease activity,pain,function,inflammation.ASAS 20=20% improvement(vs.baseline)and an absolute change≥1 units on a 0-10 scale(0=no disease activity;10=high disease activity)for ≥3 domains,and no worsening in remaining domain.
- BASDAI score comparing to baseline [ Time Frame: 48 weeks ]
- BASFI score comparing to baseline [ Time Frame: 48 weeks ]the Bath Ankylosing Spondylitis Functional Index
- Imageology [ Time Frame: 48 weeks ]
The bone marrow of the whole spine (from C2 to S1) can be detected by Magnetic resonance imaging (MRI) scan. The MRI sequence included a T1-weighted turbo spin-echo (TSE) sequence and a fat-saturated short tau inversion recovery (STIR) sequence.
MR images were first analyzed using the ASspiMRI-a scoring system , which is based on grading disease activity on a scale of 0 to 6. In addition to the ASspiMRI-a scoring system, the inflammation area and average intensityof each inflammatory site were calculated. The background value (BV) was obtained by taking 10 normal sites of the vertebral body of 1 layer and calculating the average. The inflammation extent of each inflammatory site was calculated by the formula:
value of inflammation area (VIA) × [value of average intensity (VAI) - BV]. The summation of the inflammation extent of all inflammatory sites in all scanning layers was defined as the total inflammation extent (TIE) of each patient.
- C-reactive protein (CRP) [ Time Frame: 12 weeks ]
- Erythrocyte sedimentation rate (ESR) [ Time Frame: 12 weeks ]
- Tumor necrosis factor alpha (TNF-α) [ Time Frame: 12 weeks ]
- Interleukin 6 (IL-6) [ Time Frame: 12 weeks ]
- Interleukin 17 (IL-17) [ Time Frame: 12 weeks ]
- Percentage of systemic T cell population [ Time Frame: 12 weeks ]
- Side effects [ Time Frame: 48 weeks ]These parameters monitored throughout the trial included body temperature, pulse rate, respiration rate, blood pressure, complete blood count (CBC), routine urine and stool testing, blood creatinine, alanine transaminase, and aspartate transaminase levels, anti-nuclear antibody testing, electrocardiogram, and chest radiographs. These data were obtained by skilled allied health professionals strictly according to the international standardized procedure when patients were enrolled in this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02809781
|Contact: Shen Huiyong, Doctorfirstname.lastname@example.org|
|Contact: Wang Peng, Doctoremail@example.com|
|Sun Yat-sen Memorial Hospital, Sun Yat-sen University||Recruiting|
|Guangzhou, Guangdong, China, 510120|
|Contact: Shen Huiyong, Doctor +8602081332612 firstname.lastname@example.org|
|Principal Investigator:||Shen Huiyong, Doctor||Sun Yat-sen Memorial Hospital, Sun Yat-sen University|